Zhang Z, Fasco M J, Huang Z, Guengerich F P, Kaminsky L S
Department of Environmental Health and Toxicology, University at Albany, State University of New York.
Drug Metab Dispos. 1995 Dec;23(12):1339-46.
Two forms of the cytochrome P450 enzyme superfamily, P4501A1 and P4501A2, that are heterogeneously distributed in populations and are induced in response to environmental factors are important because of their capacity to bioactivate procarcinogens. Phenotyping P4501A1 and P4501A2 in individuals will thus provide assessments of those individuals' susceptibility to procarcinogens. The anticoagulant drug warfarin is metabolized by human P4501A1 and P4501A2, and we have characterized this metabolism for the R-warfarin enantiomer as a potential in vivo probe. cDNA-expressed human P4501A1 and P4501A2 are regioselective for R-warfarin 6- and 8-hydroxylation with very similar KM values: 1.4 mM (6-hydroxylation), 1.2 mM (8-hydroxylation), 1.6 mM (6-hydroxylation), and 1.4 mM (8-hydroxylation), respectively, indicating possible binding competition for R-warfarin between the two forms. However, when comparing 6- and 8-hydroxylation, P4501A1 showed weak regioselectivity for 8-hydroxylation, whereas P4501A2 exhibited strong regioselectivity for 6-hydroxylation, with 6-hydroxylation/8-hydroxylation ratios of 0.6 and 5.0, respectively. These findings were confirmed by using microsomes from 2,3,7,8-tetrachlorodibenzo-p-dioxin-treated HepG2 and MCF-7 cells expressing only P4501A1 (ratios of 0.7), and from human hepatic microsomal preparations containing only P4501A2 (average ratios of 4.0). P4501A2 levels in the liver preparations, as assessed by densitometry of immunoblots, correlated with R-warfarin 6-hydroxylation rates (r2 = 0.83) and caffeine 3-demethylation rates (r2 = 0.67), but not with R-warfarin 8-hydroxylation rates. P450s 2A6, 2B6, 2C9, 2D6, 2E1, and 3A4 did not yield either 6- or 8-hydroxy-warfarin from R-warfarin. We conclude that R-warfarin 6-hydroxylation rates are markers for human hepatic P4501A2, whereas ratios of 6-hydroxylation/8-hydroxylation could be used in vitro as a marker for P4501A1.
细胞色素P450酶超家族的两种形式,即P4501A1和P4501A2,在人群中呈异质性分布,并可因环境因素而被诱导,因其具有生物活化前致癌物的能力而显得尤为重要。因此,对个体的P4501A1和P4501A2进行表型分析将有助于评估这些个体对前致癌物的易感性。抗凝血药物华法林可被人P4501A1和P4501A2代谢,我们已将R-华法林对映体的这种代谢特性作为一种潜在的体内探针进行了表征。cDNA表达的人P4501A1和P4501A2对R-华法林的6-和8-羟基化具有区域选择性,其米氏常数(KM)非常相似:分别为1.4 mM(6-羟基化)、1.2 mM(8-羟基化)、1.6 mM(6-羟基化)和1.4 mM(8-羟基化),这表明两种形式之间可能存在对R-华法林的结合竞争。然而,在比较6-和8-羟基化时,P4501A1对8-羟基化的区域选择性较弱,而P4501A2对6-羟基化具有较强的区域选择性,6-羟基化/8-羟基化的比率分别为0.6和5.0。使用来自仅表达P4501A1的2,3,7,8-四氯二苯并对二恶英处理的HepG2和MCF-7细胞的微粒体(比率为0.7),以及来自仅含有P4501A2的人肝微粒体制剂(平均比率为4.0),证实了这些发现。通过免疫印迹的光密度测定法评估,肝制剂中的P4501A2水平与R-华法林6-羟基化率(r2 = 0.83)和咖啡因3-去甲基化率(r2 = 0.67)相关,但与R-华法林8-羟基化率无关。P450 2A6、2B6、2C9、2D6、2E1和3A4不能将R-华法林转化为6-或8-羟基华法林。我们得出结论,R-华法林6-羟基化率是人类肝脏P4501A2的标志物,而6-羟基化/8-羟基化的比率在体外可作为P4501A1的标志物。